Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will release its second quarter 2026 financial results on July 30, 2026, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The webcast and replay will be available in the Investors section of neurocrine.com.

News Market Reaction – NBIX

-1.91%

-1.91% Session close to close

In the Jul 10 session, NBIX declined 1.91%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Neurocrine set the timing for its Q2 2026 results and investor call on July 30, 2026, consistent wit...

Analysis

Neurocrine set the timing for its Q2 2026 results and investor call on July 30, 2026, consistent with prior conferences,earnings routines. With low short interest but recent net insider selling, investors may focus next on the actual earnings quality and outlook details.

Key Figures

Q2 2026 press release time: 1:00 p.m. PT / 4:00 p.m. ET Q2 2026 conference call time: 1:30 p.m. PT / 4:30 p.m. ET Conference call date: July 30, 2026 +1 more

4 metrics

Q2 2026 press release time 1:00 p.m. PT / 4:00 p.m. ET Scheduled July 30, 2026 earnings release

Q2 2026 conference call time 1:30 p.m. PT / 4:30 p.m. ET Second quarter 2026 results call on July 30, 2026

Conference call date July 30, 2026 Second quarter 2026 financial results events

Webcast replay duration approximately one month Archive period for Q2 2026 results webcast replay

Previous Conferences,earnings Reports

5 past events · Latest: Apr 14 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 14	Earnings call scheduling	Neutral	+0.5%	Set Q1 2026 results release and conference call timing and access details.
Jan 21	Earnings call scheduling	Neutral	+1.4%	Announced Q4 and year-end 2025 results release date and webcast logistics.
Oct 07	Earnings call scheduling	Neutral	+1.5%	Scheduled Q3 2025 earnings release and conference call with dial-in details.
Jul 09	Earnings call scheduling	Neutral	+1.1%	Set Q2 2025 results timing and outlined the planned earnings webcast.
Apr 14	Earnings call scheduling	Neutral	+1.3%	Outlined Q1 2025 earnings release schedule and investor webcast information.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Similar past conference-call scheduling notices for earnings have typically coincided with small positive stock moves.

Key Terms

tardive dyskinesia, congenital adrenal hyperplasia, prader-willi syndrome, endometriosis, +1 more

5 terms

tardive dyskinesia medical

"includes FDA-approved treatments for tardive dyskinesia, chorea associated"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

congenital adrenal hyperplasia medical

"classic congenital adrenal hyperplasia, hyperphagia in patients"

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

prader-willi syndrome medical

"hyperphagia in patients with Prader-Willi syndrome, endometriosis*"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

endometriosis medical

"classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,*"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well"

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call and Webcast Scheduled for Thursday, July 30

SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026.

The schedule for the press release and conference call / webcast is as follows:

• Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
• Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-347-6865
• International Dial-In Number: 203-518-9757
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)  

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results-302822071.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) release Q2 2026 financial results?

Neurocrine Biosciences will release its Q2 2026 financial results on July 30, 2026 at 1:00 p.m. PT (4:00 p.m. ET). According to Neurocrine, this will precede a conference call and webcast scheduled thirty minutes later the same day.

What time is the Neurocrine Biosciences (NBIX) Q2 2026 earnings conference call and webcast?

The Q2 2026 Neurocrine Biosciences earnings call is on July 30, 2026 at 1:30 p.m. PT (4:30 p.m. ET). According to Neurocrine, investors can join via telephone or live webcast hosted in the Investors section of its website.

How can investors access the Neurocrine Biosciences (NBIX) Q2 2026 earnings webcast?

Investors can access the Neurocrine Biosciences Q2 2026 webcast through the Investors section at neurocrine.com. According to Neurocrine, a live stream will be offered, with an on-demand replay available about one hour after the event.

What are the dial-in numbers for the Neurocrine Biosciences (NBIX) Q2 2026 conference call?

For the Q2 2026 call, U.S. participants can dial 800-347-6865, and international callers can dial 203-518-9757. According to Neurocrine, investors should use conference ID NBIX to access the live earnings discussion.

Will a replay be available for the Neurocrine Biosciences (NBIX) Q2 2026 earnings webcast?

A replay of the Neurocrine Biosciences Q2 2026 webcast will be available about one hour after the event. According to Neurocrine, the archived webcast will remain accessible on its website for approximately one month for investors.

What does Neurocrine Biosciences (NBIX) focus on in its biopharmaceutical portfolio?

Neurocrine Biosciences focuses on treatments for neurological, psychiatric, endocrine and immunological disorders. According to Neurocrine, its portfolio includes FDA-approved therapies for tardive dyskinesia, Huntington’s chorea, congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids, plus multiple mid- to late-stage pipeline programs.